Steven Pieper Sells 27,600 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 27,600 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $8.52, for a total value of $235,152.00. Following the transaction, the insider owned 1,366,053 shares of the company’s stock, valued at approximately $11,638,771.56. The trade was a 1.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total transaction of $147,900.00.

Xeris Biopharma Stock Down 3.0%

XERS stock opened at $8.67 on Thursday. The stock has a market cap of $1.50 billion, a PE ratio of 144.50 and a beta of 0.62. The firm’s 50-day simple moving average is $6.76 and its 200 day simple moving average is $6.66. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $4.82 and a fifty-two week high of $10.08. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The firm had revenue of $83.13 million during the quarter, compared to analyst estimates of $79.83 million. As a group, sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Institutional Trading of Xeris Biopharma

A number of institutional investors have recently made changes to their positions in XERS. Vanguard Group Inc. increased its stake in shares of Xeris Biopharma by 13.8% during the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after acquiring an additional 1,358,760 shares during the period. Geode Capital Management LLC raised its holdings in Xeris Biopharma by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock worth $33,571,000 after purchasing an additional 135,815 shares in the last quarter. State Street Corp lifted its position in Xeris Biopharma by 10.1% in the fourth quarter. State Street Corp now owns 4,116,924 shares of the company’s stock worth $32,318,000 after purchasing an additional 378,595 shares during the period. Qube Research & Technologies Ltd lifted its position in Xeris Biopharma by 6.0% in the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock worth $26,657,000 after purchasing an additional 185,063 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Xeris Biopharma presently has a consensus rating of “Hold” and a consensus price target of $10.80.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.